Intended use: The SALSA MLPA probemix P405 CMT1 is an in vitro diagnostic (IVD)¹ or a research use only (RUO) assay for the detection of deletions or duplications in the human PMP22, MPZ and GJB1 genes, in order to confirm a potential cause and clinical diagnosis for Charcot-Marie-Tooth disease type 1 (CMT1). This assay can also be used for the detection of deletions in the human PMP22 gene, in order to confirm a potential cause and clinical diagnosis for hereditary neuropathy with liability to pressure palsies (HNPP). This assay is for use with human DNA extracted from peripheral blood or saliva. This product can also be used for molecular genetic testing of at-risk family members.
Deletions or duplications obtained with the P405 CMT1 probemix must be confirmed by another technique. In particular, deletions or duplications detected by only a single probe always require validation by another method. Most defects in MPZ and GJB1, and some defects in PMP22 are point mutations, none of which will be detected by MLPA. It is therefore recommended to use this SALSA MLPA probemix in combination with sequence analysis of the aforementioned genes. This assay is not intended to be used as a standalone assay for clinical decisions. The results of this test must be interpreted by a clinical molecular geneticist or equivalent.

1 Please note that this probemix is for In Vitro Diagnostic (IVD) use in the countries specified at the end of this product description. In all other countries, the product is for Research Use Only (RUO).

Clinical background: Inherited peripheral neuropathies are among the most common genetic neuromuscular disorders worldwide. The most common form is Charcot-Marie-Tooth (CMT) disease. Prevalence of CMT and related disorders has been estimated to be between 1:2500 and 1:1214. Clinical symptoms of CMT include distal muscle weakness and atrophy, sensory loss, depressed tendon reflexes and high-arched feet (pes cavus). At present, more than 80 genes are known to be associated with different types of CMT. The disease can be inherited in an autosomal dominant, autosomal recessive or X-linked manner.

CMT type 1 (CMT1) is a demyelinating peripheral neuropathy which is usually slowly progressive. Several subtypes exist. CMT1A accounts for ~70-80% of all CMT1 cases and this subtype is mainly caused by a ~1.5 Mb duplication on chromosome 17p, including the peripheral myelin protein 22 (PMP22) gene and flanking regions. The de novo rate of PMP22 duplications in CMT1 patients is ~10-20%. Furthermore, CMT1A can be caused by activating point mutations in this gene. Increased PMP22 gene dosage leads to altered nerve conduction velocity, which is the main cause of the clinical manifestations in CMT1A.
Another subtype of CMT disease is hereditary neuropathy with liability to pressure palsies (HNPP), which is characterized by repeated focal pressure neuropathies such as carpal tunnel syndrome and peroneal palsy with foot drop. PMP22 is the only gene known to be associated with HNPP. A contiguous gene deletion of chromosome 17p12 that includes PMP22 is present in approximately 80% of affected individuals; the remaining 20% have a pathogenic variant in PMP22. The prevalence of HNPP is estimated at two to five cases per 100.000 individuals. However, the majority of individuals with HNPP probably remain undiagnosed due to the mild phenotype.

CMT type 1B accounts for ~10-12% of all CMT1 cases and is caused by defects in the myelin protein-zero (MPZ) gene. MPZ is important in formation and stabilisation of peripheral nerve myelin and interacts with PMP22. Defects in the MPZ gene cause progressive slowing of nerve conduction and hypertrophy of Schwann cells. Mutations in MPZ can also lead to the more severe polyneuropathies, Dejerine-Sottas syndrome (DSS) and congenital hypomyelinating neuropathy (CHN), as well as several subtypes of CMT2. CMT1A and 1B are clinically indistinguishable; classification is based solely on molecular findings.

X-linked CMT (CMTX) accounts for ~10-15% of all CMT cases and the main subtype, CMTX1, is caused by defects in the Gap Junction Beta-1 (GJB1, also known as connexin-32) gene. Carrier females are often asymptomatic, or may experience only mild symptoms. Affected males present with moderate to severe motor and sensory neuropathy. Deafness and central nervous symptoms have been described in some CMTX1 patients. Pathogenic variants in the GJB1 coding region account for ~90% of CMTX1 cases and deletions of GJB1 have been documented in rare cases. No duplications of the GJB1 gene have been reported.

More information on CMT and HNPP can be found on:
Clinical Utility Gene Card: https://www.nature.com/articles/ejhg201075
Gene Reviews: http://www.ncbi.nlm.nih.gov/books/NBK1358/,
https://www.ncbi.nlm.nih.gov/books/NBK1392/, https://www.ncbi.nlm.nih.gov/books/NBK1374/.

Probemix content: The SALSA MLPA Probemix P405-B1 CMT1 contains 42 MLPA probes with amplification products between 130 and 445 nucleotides (nt). This includes 15 probes located in the 17p12 region, two flanking probes, seven probes in the MPZ gene, and five probes in the GJB1 gene. In addition, 10 reference probes are included that detect autosomal chromosomal locations and three probes detecting locations on the X-chromosome. Complete probe sequences and the identity of the genes detected by the reference probes are available online (www.mlpa.com).

This probemix contains nine quality control fragments generating amplification products between 64 and 105 nt: four DNA Quantity fragments (Q-fragments), two DNA Denaturation fragments (D-fragments), one Benchmark fragment, and one chromosome X and one chromosome Y-specific fragment. More information on how to interpret observations on these control fragments can be found in the MLPA General Protocol and online at www.mlpa.com.